Cost and Coverage of Originator and Biosimilar Ustekinumab Products in Medicare Part D.

Castle G, Carrier MA, Sachs RE, Keating NL, Huskamp HA, Dusetzina SB

Open source

DOI
10.1001/jamanetworkopen.2026.31556
Published
2026 Aug 3
Container
JAMA network open
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1001/jamanetworkopen.2026.31556,
  title = {Cost and Coverage of Originator and Biosimilar Ustekinumab Products in Medicare Part D.},
  author = {Castle G and Carrier MA and Sachs RE and Keating NL and Huskamp HA and Dusetzina SB},
  year = {2026},
  journal = {JAMA network open},
  doi = {10.1001/jamanetworkopen.2026.31556},
  url = {https://doi.org/10.1001/jamanetworkopen.2026.31556}
}

RIS

TY  - JOUR
TI  - Cost and Coverage of Originator and Biosimilar Ustekinumab Products in Medicare Part D.
AU  - Castle G
AU  - Carrier MA
AU  - Sachs RE
AU  - Keating NL
AU  - Huskamp HA
AU  - Dusetzina SB
PY  - 2026
JO  - JAMA network open
DO  - 10.1001/jamanetworkopen.2026.31556
UR  - https://doi.org/10.1001/jamanetworkopen.2026.31556
ER  - 

APA

G, C., MA, C., RE, S., NL, K., HA, H., & SB, D. (2026). Cost and Coverage of Originator and Biosimilar Ustekinumab Products in Medicare Part D.. JAMA network open. https://doi.org/10.1001/jamanetworkopen.2026.31556

Source records